Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Salvatore Corallo, Ettore D’Argento, Antonia Strippoli, Michele Basso, Santa Monterisi, Sabrina Rossi, Alessandra Cassano, Carlo M. Barone

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

© 2017, Springer International Publishing Switzerland. The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC) has dramatically improved patients’ prognosis and quality of life (QoL). Unfortunately, after an initial and sometimes durable benefit from EGFR-TKI therapy, all patients with EGFR-mutant lung cancer eventually become resistant to the treatment and experience disease progression. In approximately 50% of these patients, genomic alterations in the EGFR kinase domain resulting in the mutant T790M are responsible for the resistance and this has led to the development of novel EGFR inhibitors active against mutant-T790M EGFR. The remaining 50% of patients with acquired resistance (AR) to EGFR-TKIs do not harbour the T790M mutation. In these cases, other mechanisms are involved in the development of AR such as perturbations of downstream pathways (e.g. K-RAS mutations), activation of alternative bypassing pathways (including c-Met, AXL, PIK3CA, BRAF), or histologic transformation. This review summarizes the main treatment strategies for this particular and heterogeneous group of “T790M-negative” patients.[Figure not available: see fulltext.]
Original languageEnglish
Pages (from-to)153-161
Number of pages9
JournalTargeted Oncology
Volume12
Issue number2
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Mutation
Switzerland
Disease Progression
Lung Neoplasms
Phosphotransferases
Quality of Life

Cite this

Corallo, S., D’Argento, E., Strippoli, A., Basso, M., Monterisi, S., Rossi, S., ... Barone, C. M. (2017). Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. Targeted Oncology, 12(2), 153-161. https://doi.org/10.1007/s11523-017-0479-4

Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. / Corallo, Salvatore; D’Argento, Ettore; Strippoli, Antonia; Basso, Michele; Monterisi, Santa; Rossi, Sabrina; Cassano, Alessandra; Barone, Carlo M.

In: Targeted Oncology, Vol. 12, No. 2, 01.04.2017, p. 153-161.

Research output: Contribution to journalArticle

Corallo, S, D’Argento, E, Strippoli, A, Basso, M, Monterisi, S, Rossi, S, Cassano, A & Barone, CM 2017, 'Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer', Targeted Oncology, vol. 12, no. 2, pp. 153-161. https://doi.org/10.1007/s11523-017-0479-4
Corallo, Salvatore ; D’Argento, Ettore ; Strippoli, Antonia ; Basso, Michele ; Monterisi, Santa ; Rossi, Sabrina ; Cassano, Alessandra ; Barone, Carlo M. / Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. In: Targeted Oncology. 2017 ; Vol. 12, No. 2. pp. 153-161.
@article{92618fce241b4a948bbfdac207173203,
title = "Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer",
abstract = "{\circledC} 2017, Springer International Publishing Switzerland. The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC) has dramatically improved patients’ prognosis and quality of life (QoL). Unfortunately, after an initial and sometimes durable benefit from EGFR-TKI therapy, all patients with EGFR-mutant lung cancer eventually become resistant to the treatment and experience disease progression. In approximately 50{\%} of these patients, genomic alterations in the EGFR kinase domain resulting in the mutant T790M are responsible for the resistance and this has led to the development of novel EGFR inhibitors active against mutant-T790M EGFR. The remaining 50{\%} of patients with acquired resistance (AR) to EGFR-TKIs do not harbour the T790M mutation. In these cases, other mechanisms are involved in the development of AR such as perturbations of downstream pathways (e.g. K-RAS mutations), activation of alternative bypassing pathways (including c-Met, AXL, PIK3CA, BRAF), or histologic transformation. This review summarizes the main treatment strategies for this particular and heterogeneous group of “T790M-negative” patients.[Figure not available: see fulltext.]",
author = "Salvatore Corallo and Ettore D’Argento and Antonia Strippoli and Michele Basso and Santa Monterisi and Sabrina Rossi and Alessandra Cassano and Barone, {Carlo M.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s11523-017-0479-4",
language = "English",
volume = "12",
pages = "153--161",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "2",

}

TY - JOUR

T1 - Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

AU - Corallo, Salvatore

AU - D’Argento, Ettore

AU - Strippoli, Antonia

AU - Basso, Michele

AU - Monterisi, Santa

AU - Rossi, Sabrina

AU - Cassano, Alessandra

AU - Barone, Carlo M.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - © 2017, Springer International Publishing Switzerland. The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC) has dramatically improved patients’ prognosis and quality of life (QoL). Unfortunately, after an initial and sometimes durable benefit from EGFR-TKI therapy, all patients with EGFR-mutant lung cancer eventually become resistant to the treatment and experience disease progression. In approximately 50% of these patients, genomic alterations in the EGFR kinase domain resulting in the mutant T790M are responsible for the resistance and this has led to the development of novel EGFR inhibitors active against mutant-T790M EGFR. The remaining 50% of patients with acquired resistance (AR) to EGFR-TKIs do not harbour the T790M mutation. In these cases, other mechanisms are involved in the development of AR such as perturbations of downstream pathways (e.g. K-RAS mutations), activation of alternative bypassing pathways (including c-Met, AXL, PIK3CA, BRAF), or histologic transformation. This review summarizes the main treatment strategies for this particular and heterogeneous group of “T790M-negative” patients.[Figure not available: see fulltext.]

AB - © 2017, Springer International Publishing Switzerland. The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC) has dramatically improved patients’ prognosis and quality of life (QoL). Unfortunately, after an initial and sometimes durable benefit from EGFR-TKI therapy, all patients with EGFR-mutant lung cancer eventually become resistant to the treatment and experience disease progression. In approximately 50% of these patients, genomic alterations in the EGFR kinase domain resulting in the mutant T790M are responsible for the resistance and this has led to the development of novel EGFR inhibitors active against mutant-T790M EGFR. The remaining 50% of patients with acquired resistance (AR) to EGFR-TKIs do not harbour the T790M mutation. In these cases, other mechanisms are involved in the development of AR such as perturbations of downstream pathways (e.g. K-RAS mutations), activation of alternative bypassing pathways (including c-Met, AXL, PIK3CA, BRAF), or histologic transformation. This review summarizes the main treatment strategies for this particular and heterogeneous group of “T790M-negative” patients.[Figure not available: see fulltext.]

UR - http://www.scopus.com/inward/record.url?scp=85012110609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012110609&partnerID=8YFLogxK

U2 - 10.1007/s11523-017-0479-4

DO - 10.1007/s11523-017-0479-4

M3 - Article

C2 - 28188446

AN - SCOPUS:85012110609

VL - 12

SP - 153

EP - 161

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 2

ER -